| ||Audit Committee||Compensation Committee||Nominating & Corporate Governance Committee|
|Frank M. Armstrong, FRCPE, FFPM |
|Frank M. Armstrong, FRCPE, FFPM|
Dr. Frank Armstrong has been a director of the Company since September 2013. An experienced, medically qualified, pharmaceutical executive with over 20 years of experience in development and management at major pharmaceutical and leading biotechnology companies in the U.K., U.S., Switzerland and Germany, Dr. Armstrong’s experience spans all aspects of the drug evaluation, development and commercialization processes.
Dr. Armstrong led Medical Science and Innovation in R&D at M...
|Frank Condella |
Director at Palladio Biosciences
Frank Condella has been a Director since March 2009 and served as Chief Executive Officer of Juniper Pharmaceuticals from December 2009 through July 2016. He remains a consultant to the Company.
Mr. Condella has over 30 years of experience in the life sciences industry. He was Chief Executive Officer of Skyepharma plc from March 2006 to September 2008, President of European Operations and Managing Director, UK at IVAX Corporation from 2002 to February 2006, and President and...
| || || |
|Cristina Csimma, PharmD, MHP |
|Cristina Csimma, PharmD, MHP|
A director of the Company since September 2010, Dr. Csimma is also a director of Vtesse Inc. (rare diseases) and has been engaged in strategic advisory roles with the biopharmaceutical and venture capital industries, as well as government and patient organizations.
Dr. Csimma was a President and the founding Chief Executive Officer of Cydan Development, Inc. (therapeutics for orphan diseases) from November 2012 until April 2014, and a director of Cydan until December 2014. She ...
|James A. Geraghty |
|James A. Geraghty|
Chairman of the Board
Jim Geraghty has been a director of the Company since May 2015 and was elected Chairman of the Board in July 2015. He is an industry leader with 30 years of strategic and leadership experience, including more than 20 years as a senior member of executive teams at biotechnology companies developing and commercializing innovative therapies. Currently an Entrepreneur in Residence at Third Rock Ventures, a leading biotech venture and company-formation fund, Mr. Geraghty also serves as Chairman of...
|Mary Ann Gray, Ph.D.
|Mary Ann Gray, Ph.D.|
Dr. Mary Ann Gray was appointed to Juniper’s board of directors in March 2016 and serves as audit committee Chair. She is an “audit committee financial expert” under applicable Securities and Exchange Commission rules.
Dr. Gray has more than 20 years of experience in the biotechnology and biopharmaceutical industry. She is currently President of Gray Strategic Advisors, LLC, a biotechnology strategic planning and advisory firm.
Previously, a Senior Analyst and Portfolio Manager fo...
|| || |
|Ann Merrifield |
Ms. Merrifield, a director of the Company since July 2015, was formerly the President and Chief Executive Officer of PathoGenetix, a genomics company. Prior to that, she spent 18 years at the Genzyme Corporation where, among other roles, she served as Senior Vice President, Business Excellence, President of Genzyme Biosurgery, and President of Genzyme Genetics. She was previously a partner at Bain and Company and an investment officer at Aetna Life & Casualty.
Ms. Merrifield earned a Bach...
|Nikin Patel, PhD, MRPharmS |
|Nikin Patel, PhD, MRPharmS|
Chief Operating Officer
Dr. Nikin Patel co-founded and was the former Chief Executive Officer of Molecular Profiles (now known as Juniper Pharma Services). He joined our board of directors in September 2013 when Molecular Profiles was acquired by Juniper Pharmaceuticals (formerly Columbia Laboratories). Dr. Patel has over 15 years’ technical experience centered on pharmaceutical analysis and formulation development. His leadership was recognized externally through the U.K.’s most prestigious industry accolade, the...
| || || |
|Alicia Secor, MBA |
|Alicia Secor, MBA|
President and Chief Executive Officer
Alicia Secor joined Juniper Pharmaceuticals as Chief Executive Officer in August 2016 and serves as a Director of the Company. Ms. Secor brings more than 25 years’ of leadership experience as a life sciences executive, with a track record in leading businesses and advancing products from clinical development through regulatory approval, commercialization, and global expansion across several therapeutic areas.
Ms. Secor joined Juniper from Zafgen, Inc., where was Chief Commercial Offi...
| || || |